XmAb®23104 + Yervoy® (ipilimumab)
Phase 1CompletedDevelopment Stage
Melanoma (Excluding Uveal Melanoma)
Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma, Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced Solid Tumors, Undifferentiated Pleomorphic Sarcoma
May 1, 2019 → Feb 15, 2024
About XmAb®23104 + Yervoy® (ipilimumab)
XmAb®23104 + Yervoy® (ipilimumab) is a phase 1 stage product being developed by ICON plc. for Melanoma (Excluding Uveal Melanoma). The current trial status is completed. This product is registered under clinical trial identifier NCT03752398. Target conditions include Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03752398 | Phase 1 | Completed |
Competing Products
20 competing products in Melanoma (Excluding Uveal Melanoma)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Binimetinib Oral Tablet | Biotrial | Phase 1 | 25 |
| Tasisulam-sodium + Paclitaxel | Eli Lilly | Phase 3 | 77 |
| [203Pb]VMT01 + [212Pb]VMT01 + Nivolumab | Perspective Therapeutics | Phase 1/2 | 33 |
| [203Pb]VMT01 + [68Ga]VMT02 | Perspective Therapeutics | Phase 1 | 25 |
| FYB206 + Keytruda | Formycon AG | Phase 1 | 25 |
| PLX3397 | Daiichi Sankyo | Pre-clinical | 23 |
| PLX3397 + Pembrolizumab | Daiichi Sankyo | Phase 1/2 | 41 |
| Trastuzumab deruxtecan | Daiichi Sankyo | Phase 2 | 52 |
| DS-8273a + Nivolumab | Daiichi Sankyo | Phase 1 | 33 |
| PLX3397 + vemurafenib | Daiichi Sankyo | Phase 1 | 33 |
| enfortumab vedotin + pembrolizumab | Astellas Pharma | Phase 2 | 52 |
| CP-461 | Astellas Pharma | Phase 2 | 52 |
| YM155 | Astellas Pharma | Phase 2 | 52 |
| YM155 + Docetaxel | Astellas Pharma | Phase 2 | 52 |
| Denileukin diftitox | Eisai | Phase 2 | 52 |
| E7080 | Eisai | Phase 1 | 33 |
| lenvatinib + pembrolizumab | Eisai | Phase 2 | 52 |
| MORAb-004 (monoclonal antibody) | Eisai | Phase 2 | 52 |
| Pembrolizumab + Lenvatinib | Eisai | Phase 2 | 52 |
| Lenvatinib + Lenvatinib + Dacarbazine | Eisai | Phase 1/2 | 41 |